The FDA has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly and Co., for treating obstructive sleep apnea in adults with obesity. Clinical trials showed significant weight loss and improvements in apnea symptoms, underscoring its effectiveness in managing weight-related health issues.
Full Story: United Press International (12/21)